Main > ONCOLOGY (**) > Multiple Myeloma>SRE Prevention*** > USA. A. DenosuMAb



USA. A. DenosuMAb's subsections
(*) CN Approval Date: 2020. 11.19
(*) USA Approval Date: 2018. 01.05
Company
Company Licensee (CN)
Patent>Assignee; Claims; No.; Etc
Patent>Total USA No.: 23
Patent>UpDate: 2021. 02.09
SRE: Skeletal-Related Events
TradeMark
TradeMark Web-Site

USA. A. DenosuMAb's products
This section has no products